[Transfusion-transmitted diseases].

Ryushi Shimoyama
{"title":"[Transfusion-transmitted diseases].","authors":"Ryushi Shimoyama","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Transfusion-transmitted infection has long been one of the major adverse reactions in blood transfusion. However, the implementation of effective screening tests makes it minor at present. Especially NAT (nucleic acid amplification test) is highly sensitive in detecting infection with HBV, HCV and HIV-1. Now the residual risk of post-transfusion hepatitis has reduced to as low as 1:100000. Not all of the blood-borne infections are included in the category of transfusion-transmitted infection, since donors are interviewed and examined for their health statuses. As to the organisms screening is not prepared or the window period infection, donor interview would be especially important. Namely, only the organisms that are cryptogenic and induce little symptoms are included in the category of transfusion-transmitted infection. Virus infections which tend to be asymptomatic are among them, such as HBV, HCV, and HIV, as well as bacteria and protozoan infection of long latency and probably prions. At present bacterial contamination is one of the major risks of blood transfusion. West Nile virus (WNV) and hepatitis E virus (HEV) have emerged as members of transfusion transmitted infection. Other newly developing blood-borne infections will be a menace to the blood safety, and thus we should be ready to prepare for preventing them. Selection of the countermeasures should be based on cost benefit analysis. Inactivation of organisms is under study, but its distant adverse effects are not yet clear. Vaccination and the clearance of organisms from the general population would be a more basic countermeasure.</p>","PeriodicalId":6338,"journal":{"name":"[Hokkaido igaku zasshi] The Hokkaido journal of medical science","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"[Hokkaido igaku zasshi] The Hokkaido journal of medical science","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Transfusion-transmitted infection has long been one of the major adverse reactions in blood transfusion. However, the implementation of effective screening tests makes it minor at present. Especially NAT (nucleic acid amplification test) is highly sensitive in detecting infection with HBV, HCV and HIV-1. Now the residual risk of post-transfusion hepatitis has reduced to as low as 1:100000. Not all of the blood-borne infections are included in the category of transfusion-transmitted infection, since donors are interviewed and examined for their health statuses. As to the organisms screening is not prepared or the window period infection, donor interview would be especially important. Namely, only the organisms that are cryptogenic and induce little symptoms are included in the category of transfusion-transmitted infection. Virus infections which tend to be asymptomatic are among them, such as HBV, HCV, and HIV, as well as bacteria and protozoan infection of long latency and probably prions. At present bacterial contamination is one of the major risks of blood transfusion. West Nile virus (WNV) and hepatitis E virus (HEV) have emerged as members of transfusion transmitted infection. Other newly developing blood-borne infections will be a menace to the blood safety, and thus we should be ready to prepare for preventing them. Selection of the countermeasures should be based on cost benefit analysis. Inactivation of organisms is under study, but its distant adverse effects are not yet clear. Vaccination and the clearance of organisms from the general population would be a more basic countermeasure.

(Transfusion-transmitted疾病)。
输血传播感染一直是输血的主要不良反应之一。然而,由于实施了有效的筛选试验,目前这一问题尚不严重。特别是核酸扩增试验(NAT)在检测HBV、HCV和HIV-1感染方面具有很高的敏感性。现在输血后肝炎的剩余风险已降至1:10万。并非所有血源性感染都包括在输血传播感染的范畴内,因为对献血者进行了面谈和健康状况检查。对于未准备好的微生物筛选或窗口期感染,供体面谈尤为重要。也就是说,只有隐源性的和引起很少症状的微生物才被包括在输血传播感染的范畴内。其中包括无症状的病毒感染,如HBV、HCV和HIV,以及长潜伏期的细菌和原生动物感染,可能还有朊病毒。目前,细菌污染是输血的主要危险之一。西尼罗病毒(WNV)和戊型肝炎病毒(HEV)已成为输血传播感染的成员。其他新出现的血源性传染病也将对血液安全构成威胁,因此我们应该做好预防的准备。对策的选择应基于成本效益分析。生物体的失活正在研究中,但其长远的不利影响尚不清楚。接种疫苗和清除普通人群中的微生物将是一个更基本的对策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信